Products billed under this code include Cellcept Oral Susp, Mycophenolate Mofetil Oral Susp.
Payment limit per 5 MG, by effective quarter, 4Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cellcept Oral Susp | Genentech, Inc. | 00004-0261-29 | 7000 | $238.00 |
| Mycophenolate Mofetil Oral Susp | Lannett Company, Inc. | 00527-5160-82 | 7000 | $238.00 |
| Mycophenolate Mofetil Oral Susp | Heritage Pharmaceuticals Inc. | 23155-0848-51 | 7000 | $238.00 |
| Mycophenolate Mofetil Oral Susp | Aurobindo Pharma Usa, Inc. | 59651-0646-26 | 7000 | $238.00 |
| Mycophenolate Mofetil Oral Susp | Ascend Laboratories, LLC | 67877-0230-22 | 7000 | $238.00 |
| Mycophenolate Mofetil Oral Susp | Northstar Rx Llc | 72603-0751-01 | 7000 | $238.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.034 | – | 5 MG | Mycop mofetil susp oral 5 mg | v1, posted September 17, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
